Effect of an N/L-type Ca channel blocker on prorenin and soluble (pro)renin receptor levels in hypertensive patients: A randomized controlled trial

Effect of an N/L-type Ca channel blocker on prorenin and soluble (pro)renin receptor levels in hypertensive patients: A randomized controlled trial - Effect of an N/L-type Ca channel blocker on prorenin and soluble (pro)renin receptor levels in hypertensive patients: A randomized controlled trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016123

Enrollment

100

Registered

2015-01-05

Start date

2015-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Patients are treated with amlodipine. Patients are treated with cilnidipine.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Essential hypertensive patients who were treated in the department of medicine II, Tokyo Women's medical university, and fulfilled following conditions were enrolled: 1, systolic blood pressure <180mmHg and diastolic blood pressure <110mmHg. 2, untreated or treated only with anti-hypertensive drugs except calcium channel blockers.

Exclusion criteria

Exclusion criteria: 1,Patients with chronic kidney disease (CKD) stage 4 or greater 2,Patients with past histories of myocardial or cerebral infarction within the previous six months 3,Expectant mothers and lactating women 4,Patiens who have allergy to amlodipine or cilnidipine

Design outcomes

Primary

Measure	Time frame
Plasma levels of prorenin and soluble (pro)renin receptor	—

Secondary

Measure	Time frame
1, blood pressure, pulse rate 2, renal function: urinary protein/creatinine ratio, urinary albumin/creatinine ratio, eGFR, cystatin C, pentosidine 3, renin-angiotenin system: plasma renin activity, plasma renin concentration, plasma aldosterone concentration 4, sympathetic nervous system: catecholamine 5, oxidative stress marker: urine 8-OHdG 6, vascular endothelial function: flow-mediated dilation(FMD) 7, atherosclerosis: cardio-ankle vascular index(CAVI), augmentation index(AI)	—

Measure

Time frame

1, blood pressure, pulse rate 2, renal function: urinary protein/creatinine ratio, urinary albumin/creatinine ratio, eGFR, cystatin C, pentosidine 3, renin-angiotenin system: plasma renin activity, plasma renin concentration, plasma aldosterone concentration 4, sympathetic nervous system: catecholamine 5, oxidative stress marker: urine 8-OHdG 6, vascular endothelial function: flow-mediated dilation(FMD) 7, atherosclerosis: cardio-ankle vascular index(CAVI), augmentation index(AI)

—

Countries

Japan

Contacts

Public ContactDaisuke Watanabe

Tokyo Women's Medical University Department of hypertension and endocrinology

dwatanabe@endm.twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026